Organic Letters
Letter
(e) Bhonde, V. R.; Looper, R. E. J. Am. Chem. Soc. 2011, 133,
20172−20174. (f) Gibbons, J. B.; Gligorich, K. M.; Welm, B. E.;
Looper, R. E. Org. Lett. 2012, 14, 4734−4737. (g) Giles, R. L.;
Sullivan, J. D.; Steiner, A. M.; Looper, R. E. Angew. Chem., Int. Ed.
2009, 48, 3116−3120. (h) Kwon, K.-H.; Serrano, C. M.; Koch, M.;
Barrows, L. R.; Looper, R. E. Org. Lett. 2014, 16, 6048. (i) Garlets, Z.
J.; Silvi, M.; Wolfe, J. P. Org. Lett. 2016, 18, 2331−2334. Ring
expansion of aziridines: (j) Butler, D. C. D.; Inman, G. A.; Alper, H. J.
Scheme 4. Synthesis/Deprotection of N-Ts Guanidine 24
Org. Chem. 2000, 65, 5887−5890. Allylic alkylation: (k) Buchi, G.;
̈
Rodriguez, A. D.; Yakushijin, K. J. Org. Chem. 1989, 54, 4494−4496.
Carbenylative amination: (l) Kitamura, M.; Yuasa, R.; Van Vranken, D.
L. Tetrahedron Lett. 2015, 56, 3027.
(4) For other recent approaches to the synthesis of saturated cyclic
guanidines that do not utilize metal catalysts, see: (a) Mailyan, A. K.;
Young, K.; Chen, J. L.; Reid, B. T.; Zakarian, A. Org. Lett. 2016, 18,
5532. (b) Fedoseev, P.; Sharma, N.; Khunt, R.; Ermolat’ev, D. S.; Van
der Eycken, E. V. RSC Adv. 2016, 6, 75202. (c) Daniel, M.; Blanchard,
F.; Nocquet-Thibault, S.; Cariou, K.; Dodd, R. H. J. Org. Chem. 2015,
80, 10624.
coupling of 23 with 4-bromobenzophenone afforded cyclic
guanidine 24 in 69% yield. We were gratified to find that
cleavage of the N-tosyl group from 24 proceeded smoothly to
provide a 70% yield of 25.
In conclusion, we have developed a new approach to the
synthesis of five- and six-membered cyclic guanidines bearing
cleavable N-sulfonyl or N-cyano protecting groups. The Pd-
catalyzed carboamination reactions proceed in generally good
chemical yields and provide products resulting from anti-
addition to the alkene. Future studies will be directed toward
improving diastereoselectivities in these reactions.
(5) Zavesky, B. P.; Babij, N. R.; Fritz, J. A.; Wolfe, J. P. Org. Lett.
2013, 15, 5420.
(6) Zavesky, B. P.; Babij, N. R.; Wolfe, J. P. Org. Lett. 2014, 16, 4952.
(7) (a) Wenzel, M.; Light, M. E.; Davis, A. P.; Gale, P. A. Chem.
Commun. 2011, 47, 7641. (b) Perez-Medrano, A.; Brune, M. E.;
Buckner, S. A.; Coghlan, J. J.; Fey, T. A.; Gopalakrishnan, M.; Gregg,
R. J.; Kort, M. E.; Scott, V. E.; Sullivan, J. P.; Whiteaker, K. L.; Carroll,
W. A. J. Med. Chem. 2007, 50, 6265. (c) Durant, G. J.; Emmett, J. C.;
Ganellin, C. R.; Miles, P. D.; Parsons, M. E.; Prain, H. D.; White, G. R.
J. Med. Chem. 1977, 20, 901.
(8) For reviews, see: (a) Garlets, Z. J.; White, D. R.; Wolfe, J. P.
(b) Wolfe, J. P. Top. Heterocycl. Chem. 2013, 32, 1. (c) Schultz, D. M.;
Wolfe, J. P. Synthesis 2012, 44, 351.
ASSOCIATED CONTENT
* Supporting Information
■
S
The Supporting Information is available free of charge on the
Experimental procedures, characterization data, and
copies of 1H and 13C NMR spectra for all new
(9) The relative stereochemistry of products illustrated in Scheme 1
and eqs 4−6 was assigned by H NMR NOE experiments. See the
Supporting Information for complete details.
1
(10) (a) Fritz, J. A.; Wolfe, J. P. Tetrahedron 2008, 64, 6838.
(b) Fritz, J. A.; Nakhla, J. S.; Wolfe, J. P. Org. Lett. 2006, 8, 2531.
(11) (a) Fornwald, R. M.; Fritz, J. A.; Wolfe, J. P. Chem. - Eur. J.
2014, 20, 8782. (b) Babij, N. R.; McKenna, G. M.; Fornwald, R. M.;
Wolfe, J. P. Org. Lett. 2014, 16, 3412.
(12) The low yield of 8n is due to competing base-mediated
hydroamination of the starting material. This hydroamination side
reaction was not observed with the less nucleophilic N-tosyl guanidine
substrates.
(13) In our prior studies on Pd-catalyzed carboamination reactions of
PMP-protected guanidines with aryl bromides (ref 1) we observed the
stereochemistry of a product closely related to 8n resulted from syn-
addition to a Z-alkene. This assignment was originally based on
analogy to the outcome of reactions of related ureas, and has since
been confirmed via NOE studies.
AUTHOR INFORMATION
■
Corresponding Author
ORCID
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
The authors thank the NIH (GM 071650) for financial support
of this work.
■
(14) For a detailed discussion of epimerization via β-hydride
elimination pathways that occur after alkene heteropalladation in the
conversion of 4-penten-1-ol derivatives to substituted tetrahydrofur-
ans, see: Hay, M. B.; Wolfe, J. P. J. Am. Chem. Soc. 2005, 127, 16468.
(15) Syn-heteropalladation reactions are believed to proceed via
organized chair-like transition states that result from a need for an
eclipsed orientation between the Pd−N bond and the alkene. In
general, reactions that proceed via syn-heteropalladation provide
products similar to 8k and 9h with much higher selectivities than in
analogous transformations that involve anti-heteropalladation. For
further discussion, see: Peterson, L. J.; Wolfe, J. P. Adv. Synth. Catal.
2015, 357, 2339.
REFERENCES
■
(1) For recent reviews on guanidine-containing natural products, see:
(a) Berlinck, R. G. S.; Romminger, S. Nat. Prod. Rep. 2016, 33, 456.
(b) Berlinck, R. G. S.; Trindade-Silva, A. E.; Santos, M. F. C. Nat. Prod.
Rep. 2012, 29, 1382−1406. (c) Berlinck, R. G. S.; Burtoloso, A. C. B.;
Trindade-Silva, A. E.; Romminger, S.; Morais, R. P.; Bandeira, K.;
Mizuno, C. M. Nat. Prod. Rep. 2010, 27, 1871−1907.
(2) For reviews on the synthesis of natural products that contain
cyclic guanidines, see: (a) Ma, Y.; De, S.; Chen, C. Tetrahedron 2015,
71, 1145. (b) Aron, Z. D.; Overman, L. E. Chem. Commun. 2004, 253.
(c) Heys, L.; Moore, C. G.; Murphy, P. J. Chem. Soc. Rev. 2000, 29, 57.
(3) Alkene diamination: (a) Hovelmann, C. H.; Streuff, J.; Brelot, L.;
Muniz, K. Chem. Commun. 2008, 2334−2336. (b) Zhao, B.; Du, H.;
Shi, Y. Org. Lett. 2008, 10, 1087−1090. C−H functionalization:
(c) Kim, M.; Mulcahy, J. V.; Espino, C. G.; Du Bois, J. Org. Lett. 2006,
8, 1073−1076. Oxidative amination: (d) Mulcahy, J. V.; Du Bois, J. J.
Am. Chem. Soc. 2008, 130, 12630−12631. Hydroamination:
(16) (a) Fujino, M.; Wakimasu, M.; Kitada, C. Chem. Pharm. Bull.
1981, 29, 2825. (b) Wakimasu, M.; Kitada, C.; Fujino, M. Chem.
Pharm. Bull. 1982, 30, 2766.
̈
̃
D
Org. Lett. XXXX, XXX, XXX−XXX